Global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020
About Biosimilars
Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.
Request Sample At: https://www.researchbeam.com/global-mab-biosimilars-2016-2020-market
Research Beam analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.
The market is divided into the following segments based on geography:
• Europe
• Asia
• ROW
Enquire About Report At: https://www.researchbeam.com/global-mab-biosimilars-2016-2020-market/enquire-about-report
Market challenge
• Physicians' reluctance to prescribe biosimilars
• For a full, detailed list, view our report
Market trend
• Emergence of biosimilars
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table Of Contents:
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Biosimilars: Overview
• Comparative analysis of generic small molecules and biosimilars
• Biosimilars market opportunities
• Challenges for new entrants
• Bio-betters
PART 05: Pipeline portfolio
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by application
• Global chronic and autoimmune diseases mAb biosimilars market
• Global oncology mAb biosimilars market
PART 08: Geographical segmentation
• Global mAb biosimilars market by geographical segmentation 2015-2020
• mAb biosimilars market in Europe
• mAb biosimilars market in Asia
• mAb biosimilars market in rest of the world
PART 09: Market drivers
• Rise in number of patent expiries
• Need for cost-effective treatment
• Reimbursement benefits for biosimilars
• Favorable government regulations
PART 10: Impact of drivers
Contact Us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
phone+1 (800) 910-6452
help@researchbeam.com
Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product.
Request Sample At: https://www.researchbeam.com/global-mab-biosimilars-2016-2020-market
Research Beam analysts forecast the spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of 4-7% during the period 2015-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global monoclonal antibody (mAb) biosimilars market 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of mAbs. The report also considers the revenues generated from the sales of drugs that are expected to be launched during the forecast period.
The market is divided into the following segments based on geography:
• Europe
• Asia
• ROW
Enquire About Report At: https://www.researchbeam.com/global-mab-biosimilars-2016-2020-market/enquire-about-report
Market challenge
• Physicians' reluctance to prescribe biosimilars
• For a full, detailed list, view our report
Market trend
• Emergence of biosimilars
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table Of Contents:
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Biosimilars: Overview
• Comparative analysis of generic small molecules and biosimilars
• Biosimilars market opportunities
• Challenges for new entrants
• Bio-betters
PART 05: Pipeline portfolio
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by application
• Global chronic and autoimmune diseases mAb biosimilars market
• Global oncology mAb biosimilars market
PART 08: Geographical segmentation
• Global mAb biosimilars market by geographical segmentation 2015-2020
• mAb biosimilars market in Europe
• mAb biosimilars market in Asia
• mAb biosimilars market in rest of the world
PART 09: Market drivers
• Rise in number of patent expiries
• Need for cost-effective treatment
• Reimbursement benefits for biosimilars
• Favorable government regulations
PART 10: Impact of drivers
Contact Us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
phone+1 (800) 910-6452
help@researchbeam.com